New Therapies Used in Renal Failure
Main Article Content
Abstract
Acute renal failure affects all organ systems, which is characterized by a sudden loss of renal function, and causes abnormalities in the control of acid-base balance, electrolytes, and divalent captions as well as extracellular fluid balance. The absolute mortality rates for ARF acquired in hospitals and intensive care units are roughly 45% and 70%, respectively, despite significant advancements in organ support devices during the previous 20 years.Additionally, the quality of life has been proposed as a beneficial addition to clinical outcome measures because it can independently predict dialysis patients' death and length of hospitalization.There are also chances of differences in the prevalence if there is difference in the survival or lifetime duration if ailment is diagnosed.
Article Details
References
Ammirati, A. L. (2020). Chronic kidney disease. Revista da AssociaçãoMédicaBrasileira, 66, s03-s09.
Beldhuis, I. E., Lam, C. S., Testani, J. M., Voors, A. A., Van Spall, H. G., Ter Maaten, J. M., &Damman, K. (2022). Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation, 145(9), 693-712.
Ebert, T., Pawelzik, S. C., Witasp, A., Arefin, S., Hobson, S., Kublickiene, K, &Stenvinkel, P. (2020). Inflammation and premature ageing in chronic kidney disease. Toxins, 12(4), 227.
Elhoseny, M., Shankar, K., &Uthayakumar, J. (2019). Intelligent diagnostic prediction and classification system for chronic kidney disease. Scientific reports, 9(1), 9583.
Forbes, A., & Gallagher, H. (2020). Chronic kidney disease in adults: assessment and management. Clinical Medicine, 20(2), 128.
Gur, E., Levy, D., Topaz, G., Naser, R., Wand, O., Kitay-Cohen, Y& Cohen-Hagai, K. (2022). Disease severity and renal outcomes of patients with chronic kidney disease infected with COVID-19. Clinical and Experimental Nephrology, 26(5), 445-452.
Janse, R. J., Fu, E. L., Dahlström, U., Benson, L., Lindholm, B., van Diepen, M & Savarese, G. (2022). Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence. European Journal of Heart Failure, 24(11), 2185-2195.
Liyanage, T., Toyama, T., Hockham, C., Ninomiya, T., Perkovic, V, Woodward, M & Jun, M. (2022). Prevalence of chronic kidney disease in Asia: a systematic review and analysis. BMJ global health, 7(1), e007525.
Levey, A. S. (2022). Defining AKD: the spectrum of AKI, AKD, and CKD. Nephron, 146(3), 302-305.Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements, 12(1), 7-11.
Lv, J. C., & Zhang, L. X. (2019). Prevalence and disease burden of chronic kidney disease. Renal fibrosis: mechanisms and therapies, 3-15.
Ma, F., Sun, T., Liu, L., & Jing, H. (2020). Detection and diagnosis of chronic kidney disease using deep learning-based heterogeneous modified artificial neural network. Future Generation Computer Systems, 111, 17-26.
Sundström, J., Bodegard, J., Bollmann, A., Vervloet, M. G., Mark, P. B., Karasik&Tangri, N. (2022). Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health–Europe, 20.Levey, A. S., Grams, M. E., & Inker, L. A. (2022). Uses of GFR and albuminuria level in acute and chronic kidney disease. New England Journal of Medicine, 386(22), 2120-2128.
Sperati, C. J., Soman, S., Agrawal, V., Liu, Y., Abdel-Kader, K., Diamantidis, C. J& National Kidney Foundation Education Committee. (2019). Primary care physicians’ perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study. PloS one, 14(8), e0221325.